DOCSLIB.ORG

Governance and Remuneration 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Governance and Remuneration 2014 Governance & remuneration reportStrategic In this section Our Board 72 Our Corporate Executive Team 76 Chairman’s letter 78 Corporate governance framework 79 Board report to shareholders Oversight and stewardship in 2014 and future actions 80 remuneration & Governance Leadership and effectiveness 82 Committee reports Audit & Risk 86 Nominations 92 Corporate Responsibility 94 Remuneration report Chairman’s annual statement 96 Annual report on remuneration 97 2014 Remuneration policy report 119 Financial statements Financial Investor information Investor GSK Annual Report 2014 71 Our Board Strategic reportStrategic Diversity Experience International experience Composition Tenure (Non-Executives) % % % % Scientific 19 Global 75 Executive 19 Up to 3 years 39 % % % % Finance 31 USA 100 Non-Executive 81 3-6 years 15 % % % % Industry 50 Europe 94 Male 69 7-9 years 23 % % % EMAP 63 Female 31 Over 9 years 23 Sir Christopher Gent 66 Skills and experience Chairman Sir Christopher has many years of experience of leading global businesses and a track record of delivering outstanding performance Governance & remuneration & Governance Nationality in highly competitive industries. He was appointed Managing Director British of Vodafone plc in 1985 and then became its Chief Executive Officer Appointment date in 1997 until his retirement in 2003. Sir Christopher was also a 1 June 2004 and as Chairman Non-Executive Director of Ferrari SpA and a member of the British on 1 January 2005 Airways International Business Advisory Board. Committee membership External appointments Corporate Responsibility Sir Christopher is a Senior Adviser at Bain & Co. Committee Chairman, Nominations, Remuneration and Finance Sir Philip Hampton 61 Skills and experience Chairman Designate Prior to joining GSK, Sir Philip chaired major FTSE 100 companies including J Sainsbury plc. He has also served as Group Finance Nationality Director at Lloyds TSB Group, BT Group plc, BG Group plc, British British Gas and British Steel plc. Sir Philip was previously appointed an Financial statements Financial Appointment date Executive Director of Lazards and a Non-Executive Director at RMC 1 January 2015. Deputy Group Plc and Belgacom SA. Until 2009, he was Chairman of UK Chairman from 1 April 2015 and Financial Investments Limited, which manages the UK Government’s Non-Executive Chairman from shareholdings in banks. 7 May 2015 External appointments Committee membership Sir Philip is currently Chairman of The Royal Bank of Scotland Group Nominations Committee plc. He is also the Senior Independent Director of Anglo American Plc, Chairman, Finance Chairman of its Remuneration Committee and member of its Audit Committee. Sir Andrew Witty 50 Skills and experience Chief Executive Officer Sir Andrew joined GSK in 1985. He has worked in the UK, South Africa, the USA and Singapore in various senior roles. In 2003, Nationality he was appointed President of Europe and joined GSK’s Corporate British Executive Team. Sir Andrew served as the Lead Non-Executive Board Investor information Investor Appointment date member for the Department for Business, Innovation and Skills to 31 January 2008 and as Chief December 2013. He was also President of the European Federation Executive Officer on 21 May of Pharmaceutical Industries and Associations until July 2013. 2008 External appointments Committee membership Sir Andrew is a member of the Prime Minister’s Business Advisory Finance Group. He is also appointed to the UK Business Ambassador Group and School of Economics & Management Advisory Board (SEM), Tsinghua University, Beijing, China. Sir Andrew is Chancellor of the University of Nottingham. Simon Dingemans 51 Skills and experience Chief Financial Officer Prior to joining GSK, Simon has over 25 years of experience in investment banking at SG Warburg and Goldman Sachs. During this Nationality time, he advised a broad range of large corporates across a number of British industry sectors, including pharmaceuticals and consumer healthcare. Appointment date Simon advised GSK for over a decade before his appointment and was 4 January 2011 and as Chief closely involved in a number of GSK’s key strategic projects. Financial Officer on 1 April 2011 External appointments Committee membership Simon is Chairman of the 100 Group and a member of the Corporate Finance Development Council for the National Theatre. 72 GSK Annual Report 2014 Strategic reportStrategic Dr Moncef Slaoui 55 Skills and experience Chairman, Global Vaccines Moncef joined GSK Vaccines in 1988 where he engineered the development of a robust vaccines pipeline. He then led Worldwide Nationality Business Development for pharmaceutical products before his Moroccan, Belgian & American appointment to lead R&D in 2006. He was given overall responsibility Appointment date for GSK’s Oncology Business in 2010; for GSK Vaccines in 2011; and 17 May 2006 for all Global Franchises in 2012. Moncef has advised the US President’s Council of Advisors on Science and Technology and he was a member of Committee membership the Board of the Agency for Science, Technology & Research (A*STAR) Finance until January 2011. He has a PhD in Molecular Biology and Immunology from Université Libre de Bruxelles and has published more than 100 scientific papers and presentations. Prior to joining GSK, Moncef was Professor of Immunology at the University of Mons, Belgium. External appointments Moncef is a member of the PhRMA and the Biotechnology Industry remuneration & Governance Organization boards in the USA and a member of the Advisory Committee to the Director of National Institutes of Health. He is also an adviser to the Qatar Foundation, and a member of the Qatar Biomedical Research Institute Scientific Advisory Committee. Moncef serves as a Non-Executive Director for the International AIDS Vaccine Initiative (IAVI). Sir Deryck Maughan 67 Skills and experience Senior Independent Sir Deryck has a wealth of international corporate and investment Non-Executive Director banking experience, having previously served as Chairman and Chief Executive Officer of Citigroup International and of Salomon Brothers Nationality Inc. He served as Vice Chairman of the New York Stock Exchange from British 1996 to 2000. Sir Deryck was a former Senior Adviser to, and Partner Appointment date of, Kohlberg Kravis Roberts & Co and previously served as a Non- 1 June 2004 and as Senior Executive Director of Thomson Reuters. Independent Non-Executive External appointments Director on 1 May 2013 statements Financial Sir Deryck is a Non-Executive Director of BlackRock Inc, Trustee of the Committee membership British Museum and of New York University Langone Medical Center. Audit & Risk, Nominations, Remuneration and Finance Professor Sir Roy Anderson 67 Skills and experience Independent Non-Executive Professor Sir Roy is a world-renowned medical scientist with advanced Director & Scientific Expert knowledge of infectious disease epidemiology and is currently Professor of Infectious Disease in the Faculty of Medicine, Imperial Nationality College, London. He is a fellow of the Royal Society, the Academy of British Medical Sciences and the Royal Statistical Society. He is an Honorary Appointment date Fellow of the Institute of Actuaries and a Foreign Associate Member of 1 October 2007 the Institute of Medicine at the US National Academy of Sciences and the French Academy of Sciences. Professor Sir Roy brings scientific Committee membership expertise to the Board’s deliberations. Nominations and Finance External appointments information Investor Professor Sir Roy is a member of the International Advisory Board of Holdingham Group and he is a Trustee of the Natural History Museum, London. He is also a member of the Vaccine International Advisory Board (VACCIAB) of AJ Pharma Holding Sdn. Bhd in Malaysia. Dr Stephanie Burns 60 Skills and experience Independent Non-Executive Stephanie is a recognised global business leader, having served as Director Chairman, President and CEO of Dow Corning Corporation until her retirement at the end of 2011. She has a strong scientific background, Nationality with a PhD in organic chemistry with an organosilicon specialty, and is American an advocate for science education. Stephanie previously sat on the US Appointment date President’s Export Council and was an Officer of the Society of Chemical 12 February 2007 Industry, American Section, as well as the past Honorary President of the UK-based parent society. Stephanie was also an Officer and Chairman Committee membership of the American Chemistry Council. Corporate Responsibility, Remuneration and Finance External appointments Stephanie was appointed a Non-Executive Director of Corning Inc. in January 2012 and a Non-Executive Director of Kellogg Company, in February 2014. GSK Annual Report 2014 73 Our Board continued Strategic reportStrategic Stacey Cartwright 51 Skills and experience Independent Non-Executive Stacey is a Chartered Accountant and has significant experience of Director global consumer businesses and of corporate finance. She served as Executive Vice President, Chief Financial Officer of Burberry Group plc Nationality until July 2013. Prior to joining Burberry Group plc in 2004, Stacey held British the role of Chief Financial Officer at Egg plc between 1999 and 2003, Appointment date and from 1988 to 1999 she worked in various finance-related positions 1 April 2011 at Granada Group plc. Committee membership The Board has determined that Stacey has recent and relevant financial Audit & Risk and Finance
Load more

Recommended publications
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* GENOCEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 372427 10 4 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 30, 2015 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    [Show full text]
  • Corporate Governance
    Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020.
    [Show full text]
  • Doug Ogden December 2006
    JPMorgan’s Hands-On China Series Views you can use Transcript – Doug Ogden December 2006 NEW REPORT Investment Opportunities in China’s Clean Energy Technology In this presentation to global investors, Douglas Ogden, Director of the China Sustainable Energy Program in Beijing and Executive Vice President of The Energy Foundation in San Francisco, discussed the numerous opportunities for clean energy technology investment in China. These opportunities depend on social investment in upstream policies that shape markets conducive to modern, clean energy technologies. China’s traditional energy technologies, based predominantly on oil and relatively dirty coal, are priced well below social costs, skewing China’s market in favor of inefficient, Doug Ogden outmoded, and heavily polluting energy technologies. The current unsustainable situation has enormous public health and environmental costs. Director, China Sustainable These conditions, however, are being gradually reversed through concerted public policy Energy Program and legal institutional capacity building supported by international non-profits, multilateral Executive Vice President, banks, and the business community. Energy Foundation Engagement in policy development and implementation can be a highly successful strategy for creating market opportunities for clean energy technologies: Witness the progress over the last 8 years that have ushered in: China’s advanced fuel economy standards—driving markets in advanced engine technologies; The national renewable energy law and wind concessions—creating
    [Show full text]
  • Annual Report of Proxy Voting Record Date
    ANNUAL REPORT OF PROXY VOTING RECORD DATE OF REPORTING PERIOD: JULY 1, 2018 - JUNE 30, 2019 FUND: VANGUARD FTSE 100 UCITS ETF --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ISSUER: 3i Group Plc TICKER: III CUSIP: G88473148 MEETING DATE: 6/27/2019 FOR/AGAINST PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT PROPOSAL #1: ACCEPT FINANCIAL STATEMENTS AND ISSUER YES FOR FOR STATUTORY REPORTS PROPOSAL #2: APPROVE REMUNERATION REPORT ISSUER YES FOR FOR PROPOSAL #3: APPROVE FINAL DIVIDEND ISSUER YES FOR FOR PROPOSAL #4: RE-ELECT JONATHAN ASQUITH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #5: RE-ELECT CAROLINE BANSZKY AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #6: RE-ELECT SIMON BORROWS AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #7: RE-ELECT STEPHEN DAINTITH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #8: RE-ELECT PETER GROSCH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #9: RE-ELECT DAVID HUTCHISON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #10: ELECT COLINE MCCONVILLE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #11: RE-ELECT SIMON THOMPSON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #12: RE-ELECT JULIA WILSON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #13: REAPPOINT ERNST & YOUNG LLP AS AUDITORS ISSUER YES FOR FOR PROPOSAL #14: AUTHORISE BOARD ACTING THROUGH THE ISSUER YES FOR FOR AUDIT AND COMPLIANCE COMMITTEE TO FIX REMUNERATION OF AUDITORS PROPOSAL #15: AUTHORISE EU POLITICAL DONATIONS AND ISSUER YES FOR FOR EXPENDITURE PROPOSAL #16: AUTHORISE ISSUE
    [Show full text]
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • Annual Review 2005
    GS2184_Review_A\W2.qxd 7/3/06 4:58 pm Page fc1 Annual Review 2005 human being Do more, feel better, live longer GS2184_Review_A\W2.qxd 9/3/06 1:28 pm Page ifc2 01 An interview with Sir Christopher Gent, Chairman, and JP Garnier, Chief Executive Officer 05 Tachi Yamada, Chairman, Research & Development, Pharmaceuticals 06 Jean Stéphenne, President and General Manager, GSK Biologicals 08 John Clarke, President, Consumer Healthcare 11 David Stout, President, Pharmaceutical Operations 14 Performance highlights 15 Business operating review 18 The Board 19 The Corporate Executive Team 20 Summary remuneration report 23 Corporate governance 24 Responsibility statements 25 Summary financial statements 26 Summary information under US GAAP 27 Shareholder information 29 Chairman and CEO’s closing letter JP Garnier (left) and Sir Christopher Gent (right) GS2184_Review_A\W2.qxd 7/3/06 5:01 pm Page 01 “Discovering important medicines, eradicating diseases, improving the quality of people’s lives and making medicines available to a greater number of people. This is what we do – and what we do matters to people.” JP Garnier, Chief Executive Officer An interview with Sir Christopher Gent, Chairman and JP Garnier, Chief Executive Officer 2005: a year of success and progress “Thanks to the efforts of our employees around the company’s pipeline is one of the largest and most world, 2005 was a very successful year for GSK,” says promising in the industry, with 149 projects in clinical JP Garnier, Chief Executive Officer. “Not only was it development (as at the end of February 2006), our best year ever from a financial standpoint, we also including 95 new chemical entities (NCEs), 29 product made substantial progress with our pipeline of line extensions (PLEs) and 25 vaccines.
    [Show full text]
  • Global Events
    GLOBAL EVENTS Education • Professional Leverage • Networking • Philanthropy Industry Icons Sep 18, 2013 New York: A Conversation With Adena T. Friedman, Chief Financial Officer, The Carlyle Group Adena Friedman, Chief Financial Officer, The Carlyle Group Bill Stone, Founder and CEO, Moderator, SS&C Technologies Jun 3, 2013 Washington: Conversation with David M. Rubenstein, Co-Founder, The Carlyle Group David M. Rubenstein, Co-Founder, The Carlyle Group Jeffrey R. Houle, Moderator, Partner, DLA Piper Apr 3, 2013 New York: Fireside Chat with Saba Capital's Boaz Weinstein Boaz Weinstein, Founder & CIO, Saba Capital Stephanie Ruhle, Moderator, Anchor, Bloomberg Oct 30, 2012 Newport Beach: A Conversation with Dr. Mohamed El-Erian of PIMCO: Investing in a Zero-Interest Rate Environment Dr. Mohamed El-Erian, Chief Executive Officer and Co-CIO, PIMCO Lupin Rahman, Moderator, Executive Vice President, PIMCO Marc Seidner, Managing Director and Generalist Portfolio Manager, PIMCO Qi Wang, Managing Director and Portfolio Manager, PIMCO Oct 16, 2012 New York: Know Yourself and Your Decision-Making Process: A Conversation with Nobel Laureate Dr. Daniel Kahneman Dr. Daniel Kahneman, Eugene Higgins Professor of Psychology and Professor of Public Affairs Emeritus, Princeton University Jason Zweig, Moderator, Columnist, Wall Street Journal Sep 19, 2012 New York: Conversation with Eric E. Schmidt, Executive Chairman of Google Eric E. Schmidt, Executive Chairman, Google Apr 30, 2012 New York: An Armchair Discussion with John J. Mack on Leadership John J. Mack, former Chairman and CEO, Morgan Stanley Joanne Pace, Moderator, former Chief Operating Officer, Morgan Stanley Investment Management Jan 25, 2012 Geneva: Philippe Jabre Talks Markets Philippe Jabre, Chief Investment Officer, Jabre Capital Partners Dec 8, 2011 Los Angeles: Dinner Event with Howard Marks, Chairman, Oaktree Capital Oct 26, 2011 Los Angeles: Renee Haugerud, Founder, CIO & Managing Principal, Galtere, Ltd.
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • What Makes a Great Chief Executive? What Makes a Great Chief Executive? Material Consists of 80% Recycled Certification
    Material consists of 80% recycled post-consumer fibre; 10% TCF (totally chlorine free); 10% ECF (elemental chlorine free). FSC certification. NAPM recycled certification. Paper mill accredited with ISO 9001 and ISO 14001 status. All responsibilities to the local environment and manufacturing processes are strictly monitored. The Whitehead Mann Leadership Debate Leadership Mann Whitehead The What makes a great Chief Executive? Chief great a makes What THE WHITEHEAD MANN LEADERSHIP DEBATE LEADERSHIP MANN WHITEHEAD THE What makes a great Chief Executive? Chief agreat What makes Contact Carol Leonard All rights reserved. No part of this publication Whitehead Mann is one of the world’s best-known leadership consultancies may be reproduced, stored in a retrieval system, working with clients to create value through people. As an independent, Whitehead Mann or transmitted in any form or by any means, international partnership, we work as a single team to deliver deep sector Ryder Court electronic, mechanical, photocopying, recording and functional expertise. We are authorities in the areas of leadership; CEO 14 Ryder Street or otherwise, without the express permission concerns; CEO characteristics and career issues at Board and CEO level. London SW1Y 6QB of the copyright owner. Our long track record is built on our contacts, judgement, the quality of our t +44 (0) 207 024 9000 © The Whitehead Mann Partnership LLP board placements and our ability to identify the CEOs of tomorrow. Over 90 f +44 (0) 207 024 9001 of Europe’s top 200 companies and most of the FTSE 100 companies and e [email protected] Fortune 500 organisations have retained Whitehead Mann.
    [Show full text]
  • United States Securities and Exchange Commission
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6*) THERAVANCE BIOPHARMA, INC. (Name of Issuer) Ordinary Shares, par value, $0.00001 (Title of Class of Securities) G8807B106 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 17, 2020 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
    [Show full text]
  • 1 Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug Erik De Clercq
    j1 1 Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug Erik De Clercq 1.1 Introduction: The Prehistory More than 50 years ago, the synthesis of IDU (iododeoxyuridine), a thymidine analogue, was described by Prusoff [1]. This compound would later become the first antiviral drug to be licensed for (topical) use in the treatment of herpes simplex virus (HSV) infections of the eye. In this sense, the advent of IDU marked the birth of the antiviral drug era. There are now about 50 licensed antiviral compounds, half of them are used for the treatment of AIDS, of which the viral origin was first recognized 27 years ago [2, 3] (2008 Nobel Prize for Medicine or Physiology was awarded to Fran¸coise Barre-Sinoussi and Luc Montagnier for their discovery of human immu- nodeficiency virus and to Harald zur Hausen for demonstrating the link between human papilloma virus (HPV) and cervical cancer). Was IDU truly the first antiviral? In retrospect, the antiviral chemotherapy era had a rather slow and unremarkable start. The first compounds quoted to have antiviral activity (against vaccinia virus) were the thiosemicarbazones [4, 5]. These compounds were also found effective against vaccinia virus infection in mice and rabbits [6–8], and one of the thiosemicarbazones, that is, N-methylisatin-b-thiosemicarbazone, even entered clinical studies for the prophylaxis of smallpox [9] just when the smallpox vaccination took over and made any further attempts to develop an antipoxvirus drug apparently superfluous. Then came the benzimidazole derivatives as inhibitors of influenza virus multi- plication [10, 11], but despite the reported effectiveness of the 5,6-dichloro-1-b-D- ribofuranosyl benzimidazole (DRB) [10, 11] against influenza virus multiplication, it was not pursued further as a potential anti-influenza virus agent.
    [Show full text]
  • DNA Methylation Patterns and Cancer
    restriction/modification system, which brought Werner Arber, Daniel Nathans and Hamilton Smith the 1978 Nobel Prize in Physiology or Medicine, and made restriction enzymes the primary tools of Charles Rodolphe Brupbacher Foundation molecular biology. Four decades have passed since then, but the role of 5-methylcytosine in eukaryotic DNA metabolism is still shrouded in mystery. We know that the sperm methylation pattern is largely The erased after fertilization and that methylation is gradually reintroduced Charles Rodolphe Brupbacher Prize during embryogenesis and differentiation, but the processes that for Cancer Research 2017 regulate the cell type- and tissue-specific methylation patterns remain is awarded to to be elucidated. We have also learned that DNA can be not only methylated, but also demethylated, and that aberrant methylation can lead to disease - including cancer. Again, how these processes are regulated remains to be discovered. However, we have learnt a great Sir Adrian Peter Bird, deal about 5-methylcytosine metabolism during the past three decades and much of our knowledge came from the laboratory of Adrian Bird. PhD Adrian spent his doctoral and postdoctoral time in Max Birnstiel’s for his contributions to our understanding laboratory, first in Edinburgh and then in Zurich, studying the amplification of ribosomal DNA in Xenopus laevis. In this organism, of the role of DNA methylation in genomic rDNA in somatic tissues is highly methylated, while the development and disease extrachromosomal amplicons are unmethylated. When he returned to Edinburgh to establish his own group, Adrian set out to study The President The President of the Foundation of the Scientific Advisory Board the methylation pattern of these loci using the newly-available methylation-sensitive restriction enzymes.
    [Show full text]